Wydanie 2/2011
str. 103

Racjonalne przesłanki do stosowania terapii łączonych w leczeniu wysiękowej postaci AMD

Rationale for Combined Therapies Use in Wet Form of Age-related Macular Degeneration Treatment

Maria Kmera-Muszyńska, Magdalena Ulińska

Katedra i Klinika Okulistyki II Wydziału Lekarskiego Warszawskiego Uniwersytetu Medycznego
Samodzielny Publiczny Kliniczny Szpital Okulistyczny w Warszawie
Kierownik: prof. dr hab. n. med. Jerzy Szaflik


Summary: Age-related Macular Degeneration (AMD), in spite of modern types of treatment introduction, is still a great challenge for ophthalmologists. Use of Vessel Endothelial Growth Factor (VEGF) inhibitors was a turning point in the wet form of AMD treatment, because VEGF plays a key role in the choroidal neovascularization development.
However, majority of patients have to be treated repeatedly, which reduces quality of life and increases expenses of treatment, making this method not completely satisfactory.
Furthermore, anti-VEGF treatment causes only partial inhibition of angiogenesis and the phenomenon of tachyphylaxis is observed. Moreover, the anatomical and functional results are not completely satisfactory and may be influenced by disease advancement and too early treatment discontinuation.
We present current possibilities of combined therapies in patients with wet form of AMD, which may give numerous benefits and improve the outcomes of treatment.

Słowa kluczowe: wysiękowa postać AMD, inhibitory VEGF, niepowodzenia leczenia AMD, terapie łączone.

Keywords: wet form of age-related macular degeneration, VEGF inhibitors, AMD treatment failure, combined therapies.


powrót

REDAKCJA NIE UDZIELA PORAD MEDYCZNYCH I NIE POŚREDNICZY W KONSULTACJACH PACJENTÓW Z LEKARZAMI